Xintela AB
1XT
Company Profile
Business description
Xintela AB is a biomedical company that develops stem cell-based treatments with a focus on osteoarthritis and hard-to-heal leg wounds as well as, through the wholly-owned subsidiary Targinta, targeted antibody-based treatments for aggressive cancers such as triple-negative breast cancer and the brain tumor glioblastoma.
Contact
Medicon Village
Lund22381
SWET: +46 462756500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13
Stocks News & Analysis
stocks
Shares leap for ASX rare earths provider
We increased our fair value based on higher expected rare earths pricing.
stocks
Does SpaceX’s sky-high valuation make sense?
SpaceX’s $1.5 trillion valuation looks expensive and risky, but not irrational.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,823.60 | 56.80 | -0.64% |
| CAC 40 | 8,041.81 | 15.55 | -0.19% |
| DAX 40 | 23,640.03 | 328.60 | -1.37% |
| Dow JONES (US) | 47,417.27 | 289.24 | -0.61% |
| FTSE 100 | 10,353.77 | 58.47 | -0.56% |
| HKSE | 25,579.52 | 319.24 | -1.23% |
| NASDAQ | 22,716.13 | 19.03 | 0.08% |
| Nikkei 225 | 54,064.58 | 960.79 | -1.75% |
| NZX 50 Index | 13,181.77 | 111.36 | -0.84% |
| S&P 500 | 6,775.80 | 5.68 | -0.08% |
| S&P/ASX 200 | 8,599.40 | 43.80 | -0.51% |
| SSE Composite Index | 4,106.96 | 26.48 | -0.64% |